4月8日,据外媒报道,细胞分析公司Celcuity宣布与辉瑞公司达成全球许可协议,辉瑞将gedatolisib(一种1b期pan-PI3K / mTOR抑制剂)专有权授予给Celcuity。Gedatolisib正在临床开发中,用于治疗ER + / HER2-阴性的晚期或转移性乳腺癌患者。
根据许可协议条款,辉瑞向Celcuity提...查看全文
美股 美股开盘 | 三大指数涨跌不一,搜狐(SOHU.US)涨超13% 2021年4月9日 20:31:45 智通财经APP获悉,4月9日(周五)美股开盘,三大指数涨跌不一。截至发稿,道指涨0.18%,标普500指数跌0.03%,纳指跌0.41%。 个股消息 细胞分析公司Celcuit... 网页链接
格隆汇4月9日丨Celcuity(CELC.US)盘前大涨38.78%报19.86美元。公司周四表示,已与辉瑞公司签署了一项全球许可协议,获得了开发和商业化辉瑞Gedatolisib的全球许可。Gedatolisib正处于临床开发阶段,用于治疗某些类型的乳腺癌患者。Celcuity表示:“来自103... 网页链接
$Celcuity(CELC)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001654954-21-001943 Act: 33 Size: 530 KB 网页链接
$Celcuity(CELC)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001654954-21-001743 Act: 34 Size: 4 MB 网页链接
$Celcuity(CELC)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001654954-21-001731 Act: 34 Size: 364 KB 网页链接
$Celcuity(CELC)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001654954-21-001622 Act: 34 Size: 72 KB 网页链接
$Celcuity(CELC)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001654954-21-001623 Act: 34 Size: 59 KB 网页链接
$Celcuity(CELC)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001019056-21-000083 Act: 34 Size: 131 KB 网页链接
$Celcuity(CELC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000914190-21-000030 Size: 13 KB 网页链接
$Celcuity(CELC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000914190-21-000031 Size: 13 KB 网页链接
$Celcuity(CELC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000914190-21-000029 Size: 17 KB 网页链接
$Celcuity(CELC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000914190-20-000471 Size: 16 KB 网页链接